Challenges in the Management of Post-COVID-19 Pulmonary Fibrosis for the Latin American Population

Ivan Cherrez-Ojeda, Arturo Cortés-Telles, Laura Gochicoa-Rangel, Génesis Camacho-Leon, Hans Mautong, Karla Robles-Velasco, Marco Faytong-Haro

Producción científica: Contribución a una revistaComentario/Debate

11 Citas (Scopus)

Resumen

This commentary aims to highlight some of the major issues (with possible solutions) that the Latin American region is currently dealing with in managing post-COVID-19 pulmonary fibrosis. Overall, there is little evidence for successful long-term COVID-19 follow-up treatment. The lack of knowledge regarding proper treatment is exacerbated in Latin America by a general lack of resources devoted to healthcare, and a lack of availability and access to multidisciplinary teams. The discussion suggests that better infrastructure (primarily multicenter cohorts of COVID-19 survivors) and well-designed studies are required to develop scientific knowledge to improve treatment for the increasing prevalence of pulmonary fibrosis in Latin America.

Idioma originalInglés
Número de artículo1393
PublicaciónJournal of Personalized Medicine
Volumen12
N.º9
DOI
EstadoPublicada - sep. 2022

Huella

Profundice en los temas de investigación de 'Challenges in the Management of Post-COVID-19 Pulmonary Fibrosis for the Latin American Population'. En conjunto forman una huella única.

Citar esto